Wellington Management Group LLP Has $16.69 Million Holdings in Immatics N.V. $IMTX

Wellington Management Group LLP increased its position in shares of Immatics N.V. (NASDAQ:IMTX) by 5.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,647,852 shares of the company’s stock after buying an additional 85,960 shares during the period. Wellington Management Group LLP’s holdings in Immatics were worth $16,693,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in IMTX. Jefferies Financial Group Inc. boosted its position in shares of Immatics by 323.4% during the 4th quarter. Jefferies Financial Group Inc. now owns 5,059,551 shares of the company’s stock worth $53,125,000 after purchasing an additional 3,864,636 shares in the last quarter. RTW Investments LP increased its position in shares of Immatics by 29.7% during the fourth quarter. RTW Investments LP now owns 11,433,354 shares of the company’s stock valued at $120,050,000 after acquiring an additional 2,617,737 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in shares of Immatics by 10.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 21,459,156 shares of the company’s stock valued at $225,322,000 after purchasing an additional 2,075,987 shares during the last quarter. Sofinnova Investments Inc. raised its position in Immatics by 54.2% in the fourth quarter. Sofinnova Investments Inc. now owns 3,435,542 shares of the company’s stock worth $36,073,000 after acquiring an additional 1,207,705 shares during the period. Finally, Perceptive Advisors LLC raised its holdings in shares of Immatics by 10.7% in the 4th quarter. Perceptive Advisors LLC now owns 10,383,456 shares of the company’s stock worth $109,026,000 after purchasing an additional 1,000,000 shares during the period. 64.41% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Perceptive Advisors Llc purchased 863,060 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The stock was bought at an average cost of $8.69 per share, with a total value of $7,499,991.40. Following the completion of the purchase, the director directly owned 11,246,516 shares in the company, valued at approximately $97,732,224.04. This represents a 8.31% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on IMTX shares. Chardan Capital restated a “buy” rating and issued a $25.00 price objective on shares of Immatics in a research note on Tuesday, May 19th. Jefferies Financial Group set a $17.00 target price on shares of Immatics in a research report on Tuesday, August 25th. Finally, Weiss Ratings cut Immatics from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, June 23rd. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $20.60.

Immatics Price Performance

Shares of Immatics stock opened at $9.56 on Monday. The firm has a market cap of $1.31 billion, a PE ratio of -5.14 and a beta of 1.33. Immatics N.V. has a 12-month low of $5.67 and a 12-month high of $12.41. The company’s fifty day simple moving average is $9.42 and its two-hundred day simple moving average is $10.01.

Immatics (NASDAQ:IMTX) last announced its quarterly earnings results on Tuesday, August 18th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06). Immatics had a negative net margin of 495.71% and a negative return on equity of 47.41%. The business had revenue of $10.44 million for the quarter, compared to analysts’ expectations of $12.42 million. As a group, sell-side analysts expect that Immatics N.V. will post -2 earnings per share for the current fiscal year.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.